With PDUFA Date Coming Up, HGSI Optimistically Outlines Launch Plans For Benlysta
This article was originally published in The Pink Sheet Daily
Executive Summary
Assuming the lupus drug gets FDA approval, HGSI and its 50-50 partner GlaxoSmithKline are ready to launch Benlysta by the end of the first quarter.
You may also be interested in...
Despite So-So Sales To Date, HGS Sees Promising Launch For Benlysta
Third quarter U.S. sales of $18.8 million disappoint some analysts, but HGS emphasizes growing patient base and multi-part commercialization plan still being implemented.
Despite So-So Sales To Date, HGS Sees Promising Launch For Benlysta
Third quarter U.S. sales of $18.8 million disappoint some analysts, but HGS emphasizes growing patient base and multi-part commercialization plan still being implemented.
Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks
The broad labeling that FDA approved for Benlysta, the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.